Travere Therapeutics, Inc.
TVTXNASDAQHealthcare● Active
$47.51
+$1.70(+3.71%)
Market Cap$4.4B
P/E Ratio—
52W High$48.61
52W Low$13.88
Travere Therapeutics, Inc. (TVTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TVTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.39
Est. -$0.30 · -30.0%
Revenue
$0.13B
Est. $0.14B · -6.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
TVTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.05 | — | — | — | $0.16B | — |
| ▼ Q2 FY2026 | May 4, 2026 | -$0.30 | -$0.39 | -30.0% | $0.13B | $0.14B | -6.6% |
| — Q1 FY2026 | Feb 19, 2026 | $0.03 | $0.03 | +0.0% | $0.13B | $0.14B | -10.3% |
| ▲ Q4 FY2025 | Oct 30, 2025 | -$0.31 | $0.28 | +190.3% | $0.16B | $0.15B | +12.2% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.28 | -$0.14 | +50.0% | $0.11B | $0.10B | +15.0% |
| ▲ Q2 FY2025 | May 1, 2025 | -$0.55 | -$0.47 | +14.6% | $0.08B | $0.09B | -8.0% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -$0.58 | -$0.73 | -25.9% | $0.07B | $0.07B | +3.3% |
| — Q4 FY2024 | Oct 31, 2024 | -$0.70 | -$0.70 | +0.0% | $0.06B | $0.07B | -12.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
-$0.39
EPS Est.
-$0.30
EPS Surpr.
-30.0%
Revenue
$0.13B
Q1 FY2026
Feb 19, 2026
EPS Actual
$0.03
EPS Est.
$0.03
EPS Surpr.
+0.0%
Revenue
$0.13B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.28
EPS Est.
-$0.31
EPS Surpr.
+190.3%
Revenue
$0.16B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.28
EPS Surpr.
+50.0%
Revenue
$0.11B
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$0.47
EPS Est.
-$0.55
EPS Surpr.
+14.6%
Revenue
$0.08B
Q1 FY2025
Feb 20, 2025Miss
EPS Actual
-$0.73
EPS Est.
-$0.58
EPS Surpr.
-25.9%
Revenue
$0.07B
Q4 FY2024
Oct 31, 2024
EPS Actual
-$0.70
EPS Est.
-$0.70
EPS Surpr.
+0.0%
Revenue
$0.06B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.92 | $1.13 | $1.40 | 2 |
| Q3 FY2027 | $0.65 | $0.80 | $0.99 | 2 |
| Q2 FY2027 | $0.52 | $0.63 | $0.79 | 2 |
| Q1 FY2027 | $0.34 | $0.41 | $0.51 | 3 |
| Q4 FY2026 | $0.41 | $0.50 | $0.63 | 3 |
| Q3 FY2026 | $-0.24 | $-0.06 | $0.22 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.3B | $0.3B | 4 |
| Q3 FY2027 | $0.2B | $0.3B | $0.3B | 5 |
| Q2 FY2027 | $0.2B | $0.2B | $0.3B | 4 |
| Q1 FY2027 | $0.2B | $0.2B | $0.3B | 4 |
| Q4 FY2026 | $0.2B | $0.2B | $0.3B | 8 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -30.0% | $44.12 | $44.91 | +1.79% |
| ▲ Q1 FY2026 | Feb 19, 2026 | +0.0% | $27.87 | $29.30 | +5.13% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +190.3% | $29.98 | $29.65 | -1.10% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +50.0% | $16.68 | $17.24 | +3.36% |
| ▲ Q2 FY2025 | May 1, 2025 | +14.6% | $20.81 | $20.76 | -0.24% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -25.9% | $23.33 | $23.58 | +1.07% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +0.0% | $17.76 | $17.50 | -1.46% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -3.5% | $9.54 | $9.24 | -3.14% |
Q2 FY2026+1.79%
Report Date
May 4, 2026
EPS Beat/Miss
-30.0%
Price Before
$44.12
Price After
$44.91
Q1 FY2026+5.13%
Report Date
Feb 19, 2026
EPS Beat/Miss
+0.0%
Price Before
$27.87
Price After
$29.30
Q4 FY2025-1.10%
Report Date
Oct 30, 2025
EPS Beat/Miss
+190.3%
Price Before
$29.98
Price After
$29.65
Q3 FY2025+3.36%
Report Date
Aug 6, 2025
EPS Beat/Miss
+50.0%
Price Before
$16.68
Price After
$17.24
Q2 FY2025-0.24%
Report Date
May 1, 2025
EPS Beat/Miss
+14.6%
Price Before
$20.81
Price After
$20.76
Q1 FY2025+1.07%
Report Date
Feb 20, 2025
EPS Beat/Miss
-25.9%
Price Before
$23.33
Price After
$23.58
Q4 FY2024-1.46%
Report Date
Oct 31, 2024
EPS Beat/Miss
+0.0%
Price Before
$17.76
Price After
$17.50
Q3 FY2024-3.14%
Report Date
Aug 1, 2024
EPS Beat/Miss
-3.5%
Price Before
$9.54
Price After
$9.24
Avg Beat Reaction+1.14%
Avg Miss Reaction-0.09%
Beat Rate5 / 8 quarters
Largest Move+5.13% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TVTX ends December
Travere Therapeutics, Inc. (TVTX) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.39 — missing the analyst consensus of $-0.30 by -30.0%. The next TVTX earnings date is expected around September 1, 2026.
Each quarter, investors track TVTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TVTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TVTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TVTX earnings · 5 questionsTravere Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. TVTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TVTX historically reports after market close (AMC).
TVTX earnings datewhen is TVTX earningsTVTX next earnings datewhen does TVTX report earningsTVTX earnings calendar
▸ Source: FMP · Travere Therapeutics, Inc. SEC filings · US GAAP · Travere Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026